COLMYC ® 10% INJECTABLE/ FLOXAVEX 100 mg/ml

Enrofloxacin

Antibacterial

COLMYC ® 10% INJECTABLE/ FLOXAVEX 100 mg/ml

Pharmaceutical form

Injectable Solution

Target species

Swine / Cattle / Sheep / Goats

Pack sizes

50 ml
100 ml
250 ml

A favor del uso responsable de los antimicrobianos.

  • Composition

    Enrofloxacin

    100 mg/ml

  • Indications for use

    Bovine:
    Treatment of respiratory diseases caused by Pasteurella multocida, Mannheimia
    haemolytica
    and Mycoplasma spp. suscptible to enrofloxacin strains.
    Treatment of mastitis acute severe caused by Escherichia coli strains suscpetible to enrofloxacin.
    Treatment of digestive infection caused by Escherichia coli strains susceptible to enrofloxacin.
    Treatment of septicemia caused by Escherichia coli strains suscpetible to ernofloxacin.
    Treatment of acute arthritis associated with mycoplasma, caused by strains of Mycoplasma bovis susceptible to enrofloxacin. In bovines younger than 2 years old.

    Porcine:
    Treatment of respiratory infections caused by Pasteurella multocida, Mycoplasma spp. and Actinobacillus pleuropneumoniae susceptible to enrofloxacin strains.
    Treatment of urinary tract infections caused by Escherichia coli strains suscpetible to enrofloxacin.
    Treatment of postpartum dysgalactia syndrome (PDS)/ mastitis, metritis, agalactia syndrome (MMA)caused by Escherichia coli and Klebsiella spp. susceptible to enrofloxacin strains.
    Treatment of digestive tract infections caused by Escherichia coli strains suceptible to enrofloxacin.
    Porcine:
    Treatment of respiratory infections caused by Pasteurella multocida, Mycoplasma spp. and Actinobacillus pleuropneumoniae susceptible to enrofloxacin strains.
    Treatment of urinary tract infections caused by Escherichia coli strains suscpetible to enrofloxacin.
    Treatment of postpartum dysgalactia syndrome (PDS)/ mastitis, metritis, agalactia syndrome (MMA)caused by Escherichia coli and Klebsiella spp. susceptible to enrofloxacin strains.
    Treatment of digestive tract infections caused by Escherichia coli strains suceptible to enrofloxacin.